Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...

Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Rhythm Pharmaceuticals in ...

Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company had revenue of $41.83 million for the quarter, compared to the consensus ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vera Therapeutics (VERA – Research Report), ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Soleno Therapeutics (SLNO – Research Report) and ...

In this article, we are going to take a look at where Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) stands against other worst high-risk high-reward growth stocks to buy. Is the Tariff Solution ...

Rhythm Pharmaceuticals (NASDAQ:RYTM) has reported a robust first quarter in 2024, with a focus on the commercial execution of ...

Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...

In a recent transaction, Joseph Shulman, the Chief Technical Officer of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), sold 10,468 ...

Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...